Segment and Geographic Information (Details) - USD ($) $ in Millions		3 Months Ended																			6 Months Ended		12 Months Ended
		Dec. 31, 2016		Oct. 01, 2016	[2]	Jul. 02, 2016	[3]	Apr. 02, 2016	[4]	Dec. 31, 2015		Sep. 26, 2015	[6]	Jun. 27, 2015		Mar. 28, 2015	[8]	Dec. 27, 2014	[9]	Sep. 27, 2014	Dec. 31, 2015	Dec. 27, 2014	Dec. 31, 2016	Jun. 27, 2015		Jun. 28, 2014
Segment Reporting Information [Line Items]
Net sales		$ 1,331.2	[1]	$ 1,261.6		$ 1,340.5		$ 1,347.3		$ 1,359.1	[5]	$ 1,273.1		$ 1,415.2	[7]	$ 967.2		$ 985.1		$ 859.6	$ 2,632.2	$ 1,844.7	$ 5,280.6	$ 4,227.1		$ 3,914.1
Operating income																					$ 67.6	289.7	$ (1,999.7)	$ 672.5		$ 571.4
Operating income %																					2.60%		(37.90%)	15.90%		14.60%
Assets		13,870.1								19,349.6				19,591.9							$ 19,349.6		$ 13,870.1	$ 19,591.9		$ 13,879.1
Capital expenditures																					77.8		106.2	137.0		171.6
Property, plant and equipment, net		870.1								886.2				932.4							886.2		870.1	932.4		779.9
Depreciation/amortization																					182.4		457.0	258.7		206.1
Tysabri® royalty stream - change in fair value		(1,115.6)	[1]	$ 377.4		$ 910.8		$ 204.4		(116.6)	[5]	$ (173.8)		69.2	[7]	$ (100.8)		$ 105.8		$ (58.9)	(57.3)	$ (46.9)	2,608.2	(78.5)		(26.6)
Consumer Healthcare International [Member]
Segment Reporting Information [Line Items]
Net sales																					833.0		1,652.2	704.6		331.1
Consumer Healthcare International [Member] | Branded OTC [Member]
Segment Reporting Information [Line Items]
Net sales																					665.9		1,349.2	368.4		0.0
Consumer Healthcare International [Member] | Other CHCI [Member]
Segment Reporting Information [Line Items]
Net sales	[10]																				167.1		303.0	336.2		331.1
CHCA | Cough/Cold [Member]
Segment Reporting Information [Line Items]
Net sales	[11]																				234.6		454.6	455.6		477.6
CHCA | Analgesics [Member]
Segment Reporting Information [Line Items]
Net sales	[11]																				173.1		343.5	375.7		433.2
CHCA | Gastrointestinal [Member]
Segment Reporting Information [Line Items]
Net sales	[11]																				195.8		335.4	384.0		398.4
CHCA | Infant Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales																					200.2		427.0	383.8		374.8
CHCA | Smoking Cessation [Member]
Segment Reporting Information [Line Items]
Net sales																					147.5		308.5	284.5		236.8
CHCA | Vitamins, Minerals, and Dietary Supplements [Member]
Segment Reporting Information [Line Items]
Net sales	[11]																				105.8		160.4	183.5		176.9
CHCA | Animal Health
Segment Reporting Information [Line Items]
Net sales																					62.3		143.7	157.0		178.0
CHCA | Other CHCA [Member]
Segment Reporting Information [Line Items]
Net sales	[11],[12]																				132.2		334.0	254.7		305.5
CHCA | CHCA
Segment Reporting Information [Line Items]
Net sales																					1,251.5		2,507.1	2,478.8		2,581.2
All countries [Domain]
Segment Reporting Information [Line Items]
Net sales	[13]																				2,632.2		5,280.6	4,227.1		3,914.1
CHCI
Segment Reporting Information [Line Items]
Net sales																					833.0		1,652.2	704.6	[14]	331.1
Operating income																					$ (148.5)		$ (2,087.4)	$ 38.2	[14]	$ 17.0
Operating income %																					(17.80%)		(126.30%)	5.40%	[14]	5.10%
Assets		4,795.2								7,083.5				7,163.0	[14]						$ 7,083.5		$ 4,795.2	$ 7,163.0	[14]	$ 767.0
Capital expenditures																					26.3		23.7	13.1	[14]	10.2
Property, plant and equipment, net		167.2								179.5				176.8	[14]						179.5		167.2	176.8	[14]	59.3
Depreciation/amortization																					81.9		210.0	72.5	[14]	33.4
Tysabri® royalty stream - change in fair value																					0.0		0.0	0.0		0.0
RXA
Segment Reporting Information [Line Items]
Net sales																					502.6		1,042.8	936.0		864.2
Operating income																					$ 181.9		$ (0.2)	$ 364.7		$ 341.5
Operating income %																					36.20%		0.00%	39.00%		39.50%
Assets		2,646.4								2,738.0				2,373.4							$ 2,738.0		$ 2,646.4	$ 2,373.4		$ 2,189.2
Capital expenditures																					12.1		20.4	41.0		31.6
Property, plant and equipment, net		129.7								118.5				113.0							118.5		129.7	113.0		92.5
Depreciation/amortization																					34.3		120.1	65.7		66.5
Tysabri® royalty stream - change in fair value																					0.0		0.0	0.0		0.0
RXA | RXA
Segment Reporting Information [Line Items]
Net sales																					502.6		1,042.8	936.0		864.2
Specialty Sciences [Member]
Segment Reporting Information [Line Items]
Net sales																					0.0		0.0	0.0		0.0
Operating income																					$ (6.5)		$ (201.2)	$ (17.6)		$ (62.5)
Operating income %																					0.00%		0.00%	0.00%		0.00%
Assets		2,775.8								5,930.2				6,040.7							$ 5,930.2		$ 2,775.8	$ 6,040.7		$ 6,124.7	[15]
Capital expenditures																					0.0		0.0	0.5		0.0	[15]
Property, plant and equipment, net		0.4								0.0				0.0							0.0		0.4	0.0		2.0	[15]
Depreciation/amortization																					0.0		0.0	1.5		1.6
Tysabri® royalty stream - change in fair value																					(57.3)		2,608.2			(26.6)
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales																					45.1		78.5	107.7		137.6
Operating income																					$ (19.5)		$ 6.1	$ 26.8		$ 46.1
Operating income %																					(43.30%)		7.80%	24.90%		33.50%
Assets		301.4								213.1				251.0							$ 213.1		$ 301.4	$ 251.0		$ 288.0
Capital expenditures																					1.4		3.0	5.6		10.4
Property, plant and equipment, net		44.5								47.3				85.8							47.3		44.5	85.8		95.7
Depreciation/amortization																					5.3		7.8	10.6		11.4
Tysabri® royalty stream - change in fair value																					0.0		0.0	0.0		0.0
All Other Segments [Member] | Active Pharmaceutical Ingredients [Member]
Segment Reporting Information [Line Items]
Net sales																					45.1		78.5	107.7		137.6
Significant Reconciling Items [Member]
Segment Reporting Information [Line Items]
Net sales																					0.0		0.0	0.0		0.0
Operating income																					$ (149.0)		$ (116.8)	$ (121.5)		$ (173.5)
Operating income %																					0.00%		0.00%	0.00%		0.00%
Assets		0.0								0.0				0.0							$ 0.0		$ 0.0	$ 0.0		$ 0.0
Capital expenditures																					0.0		0.0	0.0		0.0
Property, plant and equipment, net		0.0								0.0				0.0							0.0		0.0	0.0		0.0
Depreciation/amortization																					0.0		0.0	0.0		0.0
Tysabri® royalty stream - change in fair value																					0.0		0.0	0.0		0.0
CHCA
Segment Reporting Information [Line Items]
Net sales																					1,251.5		2,507.1	2,478.8		2,581.2
Operating income																					$ 209.2		$ 399.8	$ 381.9		$ 402.8
Operating income %																					16.70%		15.90%	15.40%		15.60%
Assets		3,351.3								3,384.8				3,763.8							$ 3,384.8		$ 3,351.3	$ 3,763.8		$ 4,510.2
Capital expenditures																					38.0		59.1	76.8		119.4
Property, plant and equipment, net		528.3								540.9				556.8							540.9		528.3	556.8		530.4
Depreciation/amortization																					60.9		119.1	108.4		93.2
Tysabri® royalty stream - change in fair value																					$ 0.0		$ 0.0	$ 0.0		$ 0.0
Net sales [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage																					13.00%		13.00%	16.00%		19.00%
All countries [Domain]
Segment Reporting Information [Line Items]
Property, plant and equipment, net										886.2											$ 886.2
Ireland
Segment Reporting Information [Line Items]
Net sales	[13]																				11.4		$ 89.1	$ 7.2		$ 0.0
Property, plant and equipment, net		2.7								1.3				1.4							1.3		2.7	1.4
United states
Segment Reporting Information [Line Items]
Net sales	[13]																				1,686.2		3,353.0	3,303.2		3,352.0
Property, plant and equipment, net		556.6								555.0				558.6							555.0		556.6	558.6
Europe [Member]
Segment Reporting Information [Line Items]
Net sales	[13]																				758.2		1,493.0	576.4		219.7
Property, plant and equipment, net		144.6								157.2				153.8							157.2		144.6	153.8
Israel
Segment Reporting Information [Line Items]
Property, plant and equipment, net		114.3								115.7				119.8							115.7		114.3	119.8
Outside United States [Member]
Segment Reporting Information [Line Items]
Net sales	[13],[16]																				176.4		345.5	340.3		$ 342.4
Property, plant and equipment, net		$ 51.9								$ 57.0				$ 98.8							$ 57.0		$ 51.9	$ 98.8

[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9

[2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million.

[3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million.

[4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million.

[5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.

[6] Includes Mylan defense-related fees of $15.6 million.

[7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.

[8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.

[9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million.

[10] (3) Consists primarily of liquids licensed product, cough/cold/allergy, analgesics and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHCI segment.

[11] Includes net sales from our OTC contract manufacturing business.

[12] Consists primarily of feminine hygiene, diabetes care, dermatological care, branded OTC, and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHCA segment.

[13] (1) We attribute net sales to countries based on sales location.

[14] (1) CHCI includes Omega activity subsequent to March 30, 2015.

[15] (2) Specialty Sciences includes activity subsequent to December 18, 2013.

[16] (2) Includes net sales generated primarily in Israel, Mexico, Australia, and Canada.